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Genetic deletion of Abcc6 disturbs 
cholesterol homeostasis in mice
Bettina Ibold1, Janina Tiemann1, Isabel Faust1, Uta Ceglarek2, Julia Dittrich2, 
Theo G. M. F. Gorgels3,4, Arthur A. B. Bergen4,5, Olivier Vanakker6, Matthias Van Gils6, 
Cornelius Knabbe1 & Doris Hendig1*
Genetic studies link adenosine triphosphate-binding cassette transporter C6 (ABCC6) mutations 
to pseudoxanthoma elasticum (PXE). ABCC6 sequence variations are correlated with altered HDL 
cholesterol levels and an elevated risk of coronary artery diseases. However, the role of ABCC6 
in cholesterol homeostasis is not widely known. Here, we report reduced serum cholesterol 
and phytosterol levels in Abcc6-deficient mice, indicating an impaired sterol absorption. Ratios 
of cholesterol precursors to cholesterol were increased, confirmed by upregulation of hepatic 
3-hydroxy-3-methylglutaryl coenzyme A reductase (Hmgcr) expression, suggesting activation of 
cholesterol biosynthesis in Abcc6−/− mice. We found that cholesterol depletion was accompanied by a 
substantial decrease in HDL cholesterol mediated by lowered ApoA-I and ApoA-II protein levels and 
not by inhibited lecithin-cholesterol transferase activity. Additionally, higher proprotein convertase 
subtilisin/kexin type 9 (Pcsk9) serum levels in Abcc6−/− mice and PXE patients and elevated ApoB 
level in knockout mice were observed, suggesting a potentially altered very low-density lipoprotein 
synthesis. Our results underline the role of Abcc6 in cholesterol homeostasis and indicate impaired 
cholesterol metabolism as an important pathomechanism involved in PXE manifestation.
Mutations in the adenosine triphosphate-binding cassette transporter C6 (ABCC6) gene are responsible for 
pseudoxanthoma elasticum (PXE), a metabolic disease, hallmarked by a progressive elastic fiber calcification of 
the skin, eyes and cardiovascular system. Yellowish papules of the neck and flexure areas are often the first clini-
cal signs of PXE, which were wrongly considered as xanthomas in early  research1. Characteristic xanthomas are 
lesions in connective tissue formed by lipid-overloaded  macrophages2. By contrast, skin lesions of PXE are due 
to morphological alterations of elastin fibers.
Recent studies verified that ABCC6 is involved in systemic pyrophosphate homeostasis although the physi-
ological function and substrates of ABCC6 remain unknown/can be only  presumed3,4. However, an in silico 
analysis from Hosen et al. showed that lipids and bile acids are particularly the most likely ABCC6  substrates5. 
Several ABCC6 sequence variations correlate with altered HDL cholesterol, triglyceride  levels6, and an increased 
coronary  risk7. A previous study demonstrated decreased HDL cholesterol plasma levels in 8-month-old 
Abcc6−/−  mice8,9. Furthermore, Guo et al. showed that a preventive treatment with atorvastatin inhibited calci-
fications in Abcc6−/−  mice9. However, the underlying mechanism why inhibition of 3-hydroxy-3-methylglutaryl 
coenzyme A reductase (HMGCR) can suppress ectopic mineralization is not  clear10. Previously, we investigated 
cholesterol biosynthesis in dermal fibroblasts of PXE patients and observed increased HMGCR activity in 
comparison to healthy controls. Moreover, we showed increased proprotein convertase subtilisin/kexin type 
9 (PCSK9) levels and altered ApoE  expression11. Elastic fiber calcification observed in PXE is associated with 
decreased pyrophosphate levels in PXE patients and Abcc6−/−  mice12,13. Thus, bisphosphonates as nonhydrolyzable 
pyrophosphate analogues are potential candidates for treatment of PXE in addition to  statins13,14. Bisphospho-
nates containing nitrogen inhibit alkaline phosphatase  directly15, which degrades pyrophosphate and, therefore, 
promotes the mineralization  process3. Moreover, both statins and bisphosphonates inhibit enzymes involved in 
the cholesterol  biosynthesis16. Cholesterol has an important structural and metabolic function. It is an essential 
cell membrane component, a starting molecule for steroid hormone synthesis and for the formation of cofactors, 
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vitamins and bile acids. But high blood cholesterol levels can have pathological consequences, for example, the 
development of vascular diseases. In addition, excessive accumulation of cholesterol is cell toxic and should 
be prevented or reduced via reverse cholesterol transport. Only hepatocytes and hormone-producing cells can 
metabolize  cholesterol17. Maintenance of cholesterol homeostasis is primarily ensured by hepatic mechanisms, 
such as cholesterol biosynthesis, receptor-mediated uptake of lipoproteins, lipoprotein secretion, cholesterol deg-
radation and storage (summarized  in18). However, cells of peripheral tissues are capable of activating cholesterol 
synthesis due to their metabolic  needs19.
Here, we used 6- and 12-month old Abcc6−/− mice to reflect an early and a late disease stage of PXE to study 
the effects of an Abcc6 deficiency on cholesterol homeostasis. In this study, we found reduced HDL and total 
cholesterol levels in the serum of 12-month-old Abcc6−/− mice. These Abcc6−/− mice also showed consistently 
lower ApoA-I and ApoA-II levels and reduced phytosterol amounts in their serum. These results indicate that 
the ABC-transporter Abcc6 plays a relevant role in cholesterol metabolism and add new insights into the patho-
physiology of PXE.
Results
Reduced serum lipid levels due to Abcc6 deficiency. In general no statistically significant differences 
were found between male and female mice. Free, esterified, and total serum cholesterol of 6-month-old Abcc6−/− 
mice were not altered in comparison to WT mice. A significant decrease of esterified and total cholesterol is 
shown for 12-month-old Abcc6−/− mice (Fig. 1A). We observed no reduction of HDL cholesterol in the serum 
of 6-month-old Abcc6−/− mice (Fig.  1B), whereas significantly decreased levels of esterified and total serum 
cholesterol in 12-month-old Abcc6−/− mice were attributed to a substantial decrease in HDL cholesterol (− 25%; 
Fig. 1B). A reduction of oxidized LDL (oxLDL) was solely detected in the serum of 12-month-old Abcc6−/− mice 
(− 17%; Fig. 1C).
Comparing 6-month-old Abcc6−/− mice and WT mice, alterations in serum concentrations of the cholesterol 
precursors lanosterol and zymosterol/desmosterol/7-dehydrocholesterol (zy/de/7dhc) were insignificant. How-
ever, lanosterol levels in serum of 12-month-old Abcc6−/− mice were decreased by 38% (Fig. 1D). A significant 
reduction in the ratio of free lanosterol to cholesterol was found in 12-month-old Abcc6−/− mice. By contrast, the 
ratio of free zy/de/7dhc to total cholesterol was significantly increased in both groups of Abcc6−/− mice compared 
to WT mice (Table 1).
We quantified lower serum plant sterol levels overall (free, esterified and total brassicasterol, campesterol, 
β-sitosterol and stigmasterol) of both groups of Abcc6−/− mice analyzed in comparison to WT mice (Fig. 2A–D). 
We detected significant reductions of both esterified campesterol (6-month-old: − 32%; 12-month-old: − 45%) 
and total campesterol (6-month-old: − 27%; 12-month-old: − 41%) of 6- and 12-month-old Abcc6 knockout mice 
(Fig. 2B). Esterified (6-month-old: − 30%; 12-month-old: − 40%) and total β-sitosterol (6-month-old: − 29%; 
12-month-old: − 39%) were also significantly reduced in 6- and 12-month-old Abcc6−/− mice (Fig. 2C). In addi-
tion, a significant reduction of free (− 41%), esterified (− 30%) and total brassicasterol (− 37%) was determined 
in the serum of 12-month-old Abcc6−/− mice (Fig. 2A). Decreased serum levels of esterified (− 33%) and total 
stigmasterol (− 32%) were also identified in 12-month-old Abcc6−/− mice (Fig. 2D). Table 1 summarizes that 
ratios of all phytosterols to cholesterol quantified were lower in both age groups of Abcc6−/− mice compared to 
WT mice. The ratios of brassicasterol (− 0.6 µg/mg), campesterol (− 5.9 µg/mg), β-sitosterol (− 1.9 µg/mg), and 
stigmasterol (− 0.2 µg/mg) to cholesterol were significantly reduced in 12-month-old Abcc6−/− mice (Table 1).
Gene expression profile of key enzymes in cholesterol biosynthesis of liver tissue. Figure 3A 
shows that the relative mRNA expression of Hmgcr was moderately increased in 6-month-old (1.5-fold) and 
12-month-old (1.3-fold) Abcc6−/− mice compared to WT mice. The transcript level of Fdft1 was significantly 
downregulated by 30% in the liver tissue of 12-month-old Abcc6−/− mice, whereas younger Abcc6−/− mice showed 
a 1.8-fold increase in Fdft1 expression. Moreover, hepatic mRNA expression of Lss was significantly elevated up 
to 1.5-fold in 6-month-old Abcc6−/− mice (Fig. 3A).
Gene expression and serum levels of apos in Abcc6 deficiency. In comparison to WT mice, expres-
sion of Apoa2 was significantly reduced in the liver samples of 6- and 12-month old Abcc6−/− mice (Fig. 3B), 
while Apoe mRNA expression was 1.5-fold higher in the liver samples of 6-month old Abcc6−/− mice. Further-
more, gene expression of Apoa1 showed a 1.4-fold increase and the transcript level of Apoc1 was 1.1-fold elevated 
in the liver tissue of 12-month old Abcc6−/− mice (Fig. 3B). ApoC-II and ApoC-III mRNA expression levels were 
not different between Abcc6−/− and WT (Suppl. Figure 1).
In addition to the gene expression analysis, we determined apo serum concentrations (Fig. 4A–D). The levels 
of ApoA-I were significantly decreased in both age classes of Abcc6−/− mice compared to WT mice (6-month-old: 
− 18%; 12-month-old: − 18%, Fig. 4A). An even stronger reduction of Apo-II serum levels was demonstrated 
in Abcc6−/− mice (6-month-old: − 36%; 12-month-old: − 34%, Fig. 4B). Twelve-month-old Abcc6−/− mice also 
showed significantly lower ApoA-IV and ApoC-I levels (− 12% and − 25%, respectively, Fig. 4C,E). As opposed to 
these reductions, ApoB was significantly increased by 12% in both 6- and 12-month-old Abcc6−/− mice (Fig. 4D). 
ApoE serum concentrations were not different between Abcc6−/− and WT mice (Fig. 4F).
Analysis of enzymes lipoprotein metabolizing in Abcc6-deficient mice. In comparison to WT 
mice, higher transcript levels of sterol o-acyltransferase 2 (Soat2) (1.6-fold) were found in the liver tissue of 
6-month-old Abcc6−/− mice, whereas expression was repressed in older Abcc6−/− mice (Fig. 5A). Furthermore, 
phospholipid transfer protein (Pltp) mRNA expression was reduced by 30% in the liver tissue of 12-month-old 
Abcc6−/− mice. Phospholipase activity of Lcat was determined in a fluorometric assay in which lower signal 
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Figure 1.  Reduced serum lipids in Abcc6 knockout mice. (A) Serum levels of free, esterified and total cholesterol of WT 
and Abcc6−/− mice (6-month-old: WT n = 28, Abcc6−/− n = 19; 12-month-old: WT n = 41, Abcc6−/− n = 40). (B) Serum levels 
of HDL and LDL + VLDL cholesterol of WT and Abcc6−/− mice (6-month-old: WT n = 8, Abcc6−/− n = 4; 12-month-old: WT 
n = 18, Abcc6−/− n = 17). (C) Quantification of oxLDL cholesterol serum levels of WT and Abcc6−/− mice (6-month-old: WT 
n = 23, Abcc6−/− n = 17; 12-month-old: WT n = 29, Abcc6−/− n = 29). (D) Serum levels of free cholesterol precursors, lanosterol 
and zymosterol/desmosterol/7-dehydrocholesterol (zy/de/7dhc) of WT and Abcc6−/− mice (6-month-old: WT n = 28, Abcc6−/− 
n = 19; 12-month-old: WT n = 41, Abcc6−/− n = 40). Data are mean ± SD; one factorial variance analysis (A,B,D) or Student’s t 
test (C); *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.
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intensity corresponds to higher enzyme activity. Figure 5B show that Lcat activity was lower by 5% in 6-month-
old Abcc6−/− mice compared to WT mice. However, differences in older mice were insignificant.
We observed significantly higher Lpl gene expression in the liver tissue of 6-month-old Abcc6−/− mice (2.5-
fold) than in WT mice. The expression of hepatic Lpl was also highly induced in 12-month-old Abcc6−/− mice 
(3.4-fold; Fig. 5C). The extrahepatic expression level of Lpl was only significantly increased in the white adipose 
tissue of 6-month-old Abcc6−/− mice (1.4-fold). The transcript level of hepatic lipase (Lipc) was significantly 
upregulated in 6-month-old Abcc6−/− mice (1.3-fold; Fig. 5D). In contrast to the elevated Lpl gene expression in 
Abcc6−/− mice, no differences of protein expression were found in these mice (Fig. 5E).
Altered gene and protein expression of Pcsk9 and LDL receptor (Ldlr) in Abcc6-deficient 
mice. The expression of Pcsk9 and Ldlr in the liver tissue of Abcc6-deficient and WT mice was simi-
lar (Fig.  6A). By contrast, the relative mRNA expression of Ldlr in the white adipose tissue of 6-month-old 
Abcc6−/− mice was higher by factor 2.4 compared to WT mice (Fig. 6B).
The Pcsk9 concentration in serum of 6-month-old Abcc6−/− mice was 67% higher than in WT mice (Fig. 6C). 
In line with this, PXE patients also had 41% higher PCSK9 serum concentrations than healthy controls (Fig. 6D).
Table 1.  Elevated cholesterol precursor to cholesterol ratios and reduction of relative plant sterol levels 
in Abcc6 knockout mice. Ratios of free cholesterol precursors [lanosterol and zymosterol/desmosterol/7-
dehydrocholesterol (zy/de/7dhc)] and total phytosterols (brassicasterol, campesterol, β-sitosterol, stigmasterol) 
to total cholesterol (μg/mg ± SD) in serum of 6- and 12-month-old WT and  Abcc6−/− mice. Student’s t test; 
*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.
Ratio (µg/mg)
6-month-old mice 12-month-old mice
WT (n = 28) Abcc6−/− (n = 19) p-value WT (n = 41) Abcc6−/− (n = 40) p-value
Lanosterolfree to  cholesteroltotal 0.21 ± 0.02 0.24 ± 0.02 0.233 0.21 ± 0.02 0.16 ± 0.01 0.005**
zy/de/dhfree to  cholesteroltotal 0.51 ± 0.02 0.62 ± 0.03 0.001** 0.44 ± 0.02 0.53 ± 0.02 0.003**
Brassicasteroltotal to  cholesteroltotal 0.51 ± 0.02 0.62 ± 0.03 0.361 0.44 ± 0.02 0.53 ± 0.02 0.003**
Campesteroltotal to  cholesteroltotal 22.58 ± 0.89 18.42 ± 2.14 0.086 25.09 ± 0.93 19.18 ± 1.20 0.001***
β-Sitosteroltotal to  cholesteroltotal 8.84 ± 0.32 6.97 ± 0.97 0.109 8.89 ± 0.33 6.99 ± 0.47 0.002**
Stigmasteroltotal to  cholesteroltotal 0.95 ± 0.03 0.94 ± 0.10 0.863 1.11 ± 0.05 0.96 ± 0.05 0.038*
Figure 2.  Reduced plant sterol levels in serum of Abcc6 knockout mice. Free, esterified and total phytosterol 
serum levels of WT and Abcc6−/− mice (6-month-old: WT n = 28, Abcc6−/− n = 19; 12-month-old: WT n = 41, 
Abcc6−/− n = 40). (A) brassicasterol, (B) campesterol, (C) β-sitosterol and (D) stigmasterol. Data are mean ± SD; 
one factorial variance analysis; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.
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Discussion
Human genetic studies have demonstrated that diverse sequence variations of well-known genes, such as 
LIPC, ABCA1 or even ABCC6, which cause PXE, are not disease-causing, but associated with decreased HDL 
 cholesterol6,7,20,21. This association could be directly related to a higher cardiovascular risk in PXE patients. 
Studies of human and mice found an increased carotid intima media  thickness22–24 due to ABCC6 deficiency, 
which correlates with higher risk for cardiovascular  complications25. In current case reports it has been noticed 
that PXE patients suffer from degenerated and calcified elastic fibers in heart tissue as well stenosis in coronary 
 arteries26,27. Furthermore, in a cardiac ischemia–reperfusion injury mice model could be demonstrated that the 
infarct size in heart tissue was increased in Abcc6−/−  mice28.
In line with a previous study by Gorgels et al.8, which reported lower total and HDL cholesterol in 8-month-
old but not in the 2.5-month-old Abcc6−/− mice, we also observed an age-dependent reduction of serum total 
(− 10%) and HDL cholesterol (− 20%) in 6-month-old Abcc6−/− mice. These reductions increased with increas-
ing age. Hence, Abcc6−/− mice at an age of 12 months presented lower concentrations of total (− 20%) and 
HDL cholesterol (− 25%). Whereas Guo et al.9, showed an increase of total cholesterol and triglyceride levels 
in 3-month-old Abcc6−/− mice. These similar studies on mice seem to give conflicting results which should be 
reasoned with different ages of analyzed animals as well with using two distinct Abcc6 knockout models by differ-
ent gene targeting  strategies8,9,29. Several studies have demonstrated that a low HDL cholesterol level is a pivotal 
and independent factor from LDL cholesterol to facilitate coronary heart  diseases30. The two most important 
Figure 3.  Altered gene expression of cholesterol biosynthetic enzymes and apolipoproteins in Abcc6 
knockout mice. (A) Relative hepatic gene expression levels of cholesterol biosynthesis enzymes [3-hydroxy-3-
methylglutaryl coenzyme A reductase (Hmgcr), farnesyl pyrophosphate synthase (Fdps), farnesyl-diphosphate 
farnesyltransferase 1 (Fdft1), geranylgeranyl pyrophosphate synthase 1 (Ggps1) and lanosterol synthase (Lss)] 
and (B) apolipoproteins (Apoa1, Apoa2, Apoa4, Apob, Apoc1 and Apoe) of WT and Abcc6−/− mice (6-month-
old: WT n = 22, Abcc6−/− n = 25; 12-month-old: WT n = 37, Abcc6−/− n = 39). Data are fold change of mean ± SD 
relative to samples of WT; by Student’s t test; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.
6
Vol:.(1234567890)
Scientific Reports |         (2021) 11:2137  | https://doi.org/10.1038/s41598-021-81573-1
www.nature.com/scientificreports/
structure elements of HDL particles are ApoA-I and ApoA-II31. The ApoA-I protein in conjunction with ABCA1 
is responsible for the biogenesis of HDL by serving as a lipid acceptor for excess  cholesterol32. Another protein 
ApoC-I regulates activities of various enzymes associated with HDL metabolism. It is responsible for the activa-
tion of LCAT and the inhibition of  LIPC33. Moreover, ApoC-I has an important influence on ApoB-mediated 
VLDL uptake in the liver. An overexpression of human ApoC1 in a murine model led to a massive increase of 
serum cholesterol and triglycerides by the accumulation of  VLDL34. Unexpectedly, an Apoc1 knockout in mice 
was not accompanied by a hypolipidemic phenotype, but rather by normal lipid concentrations in the serum 
under a normal chow  diet35. In this study, we showed for the first time that an Abcc6 deficiency leads to a reduc-
tion of ApoA-I, ApoA-II, ApoA-IV and ApoC-I serum concentration in Abcc6−/− mice. This observation might 
explain the decreased HDL cholesterol level of Abcc6−/− mice and further indicates reduced HDL biogenesis. 
Another explanation for decreased HDL cholesterol might be altered hepatic expression of Abca1. However, we 
previously showed that hepatic Abca1 expression is not altered in Abcc6−/−  mice36. A recent study by Dergunov 
et al. 2020 showed that increased ApoA-I serum levels might be associated with higher ApoA-I release of HDL 
 particles37. Released ApoA-I determines the increase of cholesterol efflux of macrophages to circulating HDL. 
Thus, low level of plasma HDL particles may be compensated by their increased potency for ApoA-I release. 
The authors suggested ApoA-I release as a new HDL functional property. This is probably not the case in HDL 
particles in Abcc6-deficient mice suggesting altered HDL functionality. The dysalphalipoproteinemia due to 
Abcc6-deficiency seen here might lead to a probably decreased flux of cholesteryl ester to the liver and conse-
quently increased hepatic cholesterol synthesis.
In contrast to cholesterol, plant sterols cannot be synthesized by mammalian cells and, thus, must be absorbed 
with the  diet38. Serum phytosterol levels, especially of campesterol and β-sitosterol, reflect intestinal cholesterol 
 absorption38 and are furthermore, inversely related to serum precursor concentrations but correlate positively 
with HDL cholesterol and negatively with cholesterol biosynthesis  activity39,40. Here, we reported for the first 
time significantly reduced serum concentrations of esterified and total phytosterols, such as campesterol and 
β-sitosterol in both 6- and 12-month-old Abcc6−/− mice. These findings provide a first indication of lower cho-
lesterol and plant sterol absorption due to Abcc6 deficiency. Perhaps the Abcc6 transporter might be partly 
responsible for functional sterol absorption, as it was demonstrated that the Abcc6 protein is expressed in several 
parts of the intestine, which are responsible for lipid absorption, particularly for cholesterol  uptake41–43. Fur-
thermore, Hosen et al. generated a ranking list for the most likely physiological substrates of ABCC6 by in silico 
docking analysis. Lipids and bile acids were identified particularly as potential ABCC6 substrates. Thereby, the 
plant sterol brassicasterol (rank 3), β-sitosterol as (rank 41) and stigmasterol as (rank 48) were highly  ranked5.
The ratio of cholesterol precursors to the cholesterol level is used for activity analysis of cholesterol 
 biosynthesis39,44. It is notable that the relative concentration of free desmosterol to cholesterol correlates posi-
tively with hepatic HMGCR activity, highlighting the rate-limiting step of cholesterol  biosynthesis45. In addi-
tion, cholesterol precursor concentrations in serum are positively related to overall cholesterol biosynthesis and 
negatively related to cholesterol absorption and HDL cholesterol  levels40. Here, we describe for the first time that 
the ratio of zy/dh/7dhc to cholesterol was significantly higher by up to 25% in both age groups of Abcc6−/− mice. 
Figure 4.  Reduced serum levels of HDL-associated apolipoproteins and elevated ApoB serum levels in Abcc6 
knockout mice. Apolipoprotein serum levels of WT and Abcc6−/− mice (6-month-old: WT n = 28, Abcc6−/− 
n = 19; 12-month-old: WT n = 41, Abcc6−/− n = 40). (A) ApoA-I, (B) ApoA-II, (C) ApoA-IV, (D) ApoB, (E) 
ApoC-I and (F) ApoE. Data are mean ± SD; one factorial variance analysis; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.
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These data support our hypothesis of an increased cholesterol biosynthesis due to Abcc6 deficiency. However, 
the ratio of lanosterol to cholesterol was unchanged in 6-month-old Abcc6−/− mice and significantly reduced in 
12-month-old Abcc6−/− mice. The precursor molecule lanosterol is able to induce the degradation of HMGCR 
 protein46, thus, reduced lanosterol levels will further trigger cholesterol synthesis. We demonstrated in previous 
cell culture experiments that dermal fibroblasts from PXE patients have a significantly higher HMGCR mRNA 
expression and activity than healthy control  cells11. Furthermore, Guo et al. observed in a previous study that a 
high dose atorvastatin treatment, a competitive HMGCR inhibitor, of Abcc6−/− mice has a preventive effect on 
vibrissae  calcification9. Statins may be able to reduce protein prenylation of G protein RhoA by the inhibition of 
HMGCR and related metabolic pathways, which activated the bone morphogenetic protein 2 (BMP2) signaling 
and, therefore, mineralization  facilitates10. Furthermore, Hosen et al. found that BMP2 signaling in Abcc6−/− mice 
are active at calcified sites, such as vibrissae and eyes. It was also demonstrated that this signaling pathway is 
upregulated in human fibroblasts from PXE patients in vitro47.
We described here for the first time that Abcc6 deficiency in mice is linked to lower plant sterol and apoli-
poprotein levels and postulate a disturbed sterol absorption and HDL metabolism. Whereas Abcg5/Abcg8 own 
there physiological function in the biliary efflux of cholesterol metabolites, we propose a physiological function 
Figure 5.  Expression alteration of lipoprotein metabolizing enzymes in Abcc6 knockout mice. (A) Relative 
hepatic gene expression levels of lipoprotein metabolizing proteins (sterol O-acyltransferase (Soat2), Lcat, 
phospholipid transfer protein (Pltp) and scavenger receptor B1 (Srb1)) of WT and Abcc6−/− mice (6-month-
old: WT n = 22, Abcc6−/− n = 25; 12-month-old: WT n = 37, Abcc6−/− n = 39). Data are fold change of mean ± SD 
relative to samples of WT. (B) The lecithin-cholesterol acyltransferase (Lcat) activity was determined in serum of 
WT and Abcc6−/− mice (6-month-old: WT: n = 22, Abcc6−/−: n = 15; 12-month-old: WT: n = 30 Abcc6−/−: n = 34). 
Data are mean ± SD. (C) Relative hepatic gene expression level of lipoprotein lipase (Lpl) and hepatic lipase 
(Lipc) of WT and Abcc6−/− mice (6-month-old: WT n = 22, Abcc6−/− n = 25; 12-month-old: WT n = 37, Abcc6−/− 
n = 39). Data are fold change of mean ± SD relative to samples of WT. (D) Relative gene expression level of Lpl in 
the kidney and white adipose tissue of WT and Abcc6−/− mice (6-month-old: WT: adipose tissue n = 22, kidney 
n = 25, Abcc6−/−: adipose tissue n = 18, kidney n = 23; 12-month-old: WT: adipose tissue n = 33, kidney n = 34, 
Abcc6−/−: adipose tissue n = 38, kidney n = 42). Data are fold change of mean ± SD relative to samples of WT. (E) 
Quantification of Lpl concentration in serum of WT and Abcc6−/− mice (6-month-old: WT: n = 23, Abcc6−/−: 
n = 21; 12-month-old: WT: n = 33 Abcc6−/−: n = 29). Data are mean ± SD; Student’s t test; *p ≤ 0.05; ***p ≤ 0.001.
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of ABCC6 in lipoprotein metabolism (e.g. packing of lipoprotein particles), probably influencing the content 
and subsequently the functional capacity of lipoprotein particles. Our results underline the role of Abcc6 in 
Figure 6.  Altered gene and protein expression analysis of proprotein convertase subtilisin/kexin type 9 (Pcsk9) 
and low-density lipoprotein receptor (Ldlr) in Abcc6 knockout mice and PXE patients. (A) Relative hepatic gene 
expression level of proprotein convertase subtilisin/kexin type 9 (Pcsk9) and LDL receptor (Ldlr) of WT and 
Abcc6−/− mice (6-month-old: WT n = 22, Abcc6−/− n = 25; 12-month-old: WT n = 37, Abcc6−/− n = 39). Data are 
fold change of mean ± SD relative to samples of WT. (B) Relative gene expression level of Ldlr in the kidney and 
white adipose tissue of WT and Abcc6−/− mice (6-month-old: WT: adipose tissue n = 22, kidney n = 25, Abcc6−/−: 
adipose tissue n = 18, kidney n = 23; 12-month-old: WT: adipose tissue n = 33, kidney n = 34, Abcc6−/−: adipose 
tissue n = 38, kidney n = 42). Data are fold change of mean ± SD relative to samples of WT. (C) Quantification of 
Pcsk9 concentration in serum of WT and Abcc6−/− mice (6-month-old: WT: n = 27, Abcc6−/−: n = 21; 12-month-
old: WT: n = 35 Abcc6−/−: n = 31). Data are mean ± SD. (D) Quantification of PCSK9 concentration in serum of 
healthy controls and PXE patients (healthy controls: n = 36, PXE patients: n = 36). Data are mean ± SD; Student’s 
t test; *p ≤ 0.05; **p ≤ 0.01.
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cholesterol homeostasis and indicate impaired cholesterol metabolism as an important pathomechanism involved 
in PXE manifestation (summarized in Fig. 7). These findings raise new questions about how cholesterol and lipid 
metabolism are regulated due to Abcc6 deficiency. Further studies are definitely necessary to understand the com-
plex gene regulatory network and tissue specificity regulating cholesterol metabolism due to ABCC6 deficiency.
Materials and methods
All experiments within this study were performed in accordance with relevant guidelines and regulations.
Animals. All experiments within this study were performed using dead animals. Mice were killed solely 
for the use of their organs or tissues without incriminating experiments. Therefore, animal preparations com-
ply with the law on animal welfare of Germany used for scientific purposes, an ethical approval for our study 
Figure 7.  Hypothetic model of Abcc6 function in cholesterol homeostasis of mice. This model summarizes 
the results obtained in this study and illustrates the possible effects of an Abcc6 loss of function in maintaining 
cholesterol homeostasis in mice. We further demonstrated a disturbed reverse cholesterol transport by 
reduction of important apolipoproteins for HDL functionality in serum of Abcc6−/− mice (ApoA-I and 
ApoA-II). We found elevated cholesterol precursors in serum of Abcc6 knockout mice (zymosterol, 
desmosterol, 7-dehydrocholesterol) as hint for an increased overall cholesterol synthesis. In a former study, 
we showed that Abcg5/Abcg8 expression in the liver of Abcc6−/− mice was induced, suggesting an increased 
sterol excretion by the  liver50. In summary, we propose that Abcc6-deficiency in mice might be accompanied 
by a reduced absorption of cholesterol and thereby phytosterols in the intestine. Green arrows indicate 
increased target expression, increased protein/metabolite concentration or activation of a pathway, red arrows 
indicate the repression of target expression or protein/metabolite concentration or inactivation of a pathway. 
See text for further details. CM chylomicron, Lpl lipoprotein lipase, Pcsk9 proprotein convertase subtilisin/
kexin type 9, Ldlr LDL receptor, IDL intermediate density lipoprotein, Abc ABC-transporter, Fdps farnesyl 
pyrophosphate synthase, Fdft1 farnesyl diphosphate farnesyl transferase 1, Ggps1 geranylgeranyl pyrophosphate 
synthase 1, Lss lanosterol synthase, IPP/DPP isopentenyl pyrophosphate/dimethyallyl pyrophosphate, GPP 
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was not required. The Abcc6−/− mice were generated on a hybrid background of C57BL/6 and 129/Ola and 
were backcrossed to C57BL/6 for more than 5  generations8. Mice were housed under standard conditions in a 
pathogen-free central animal facility of Bielefeld University (Germany) and kept with water and food (normal 
chow) ad  libitum and therefore non-fasted blood samples were used for lipid analysis. In the present study, 
we used Abcc6 (+/+) littermates and pure C57BL/6 mice as WT control mice. Mice (males and females), aged 
6 months ± 2 weeks and 12 months ± 4 weeks, were anesthetized intraperitoneal with 0.65 mg ketamine, 0.02 mg 
acepromazine and 0.13 mg xylazine per 10 g bodyweight and sacrificed by bleeding subsequent to cervical dislo-
cation. After opening the thorax, the right ventricle of the heart was cut for liver perfusion via the hepatic portal 
vein with PBS. Liver, kidneys and perigonadal white adipose tissue were collected, immediately frozen in liquid 
 N2 and stored at − 80 °C until use. Serum was obtained by centrifugation of the blood samples collected at 3000g 
for 10 min at room temperature. Serum was stored at − 80 °C until  use36.
Patient characteristics. The diagnosis of PXE in all patients was consistent with the consensus criteria 
reported. Eleven male [mean ± SD age, 47.8 ± 5.5 years] and 25 female [38.7 ± 11.4 years] PXE patients, and 11 
male [47.8 ± 5.5 years] and 25 female [38.7 ± 11.4 years] blood donors were included in this study as healthy con-
trols. All patients and controls gave their written informed consent for participation in the study. The study was 
conducted in accordance with the Declaration of Helsinki and approved by the ethics Committee of the HDZ 
NRW, Department of Medicine, Ruhr University of Bochum (registry no. 32/08). Selected lipid parameters were 
measured and are shown in Supplementary Table 2.
Serum levels of mouse pre-heparin Lpl. The concentration of pre-heparin Lpl in serum was measured 
via a commercial enzyme-linked immunosorbent assay Mouse LPL ELISA Kit (Biozol Diagnostica GmbH, Ech-
ing, Germany), according to the manufacturer’s protocol. Samples were diluted 1:20.
Serum levels of human and mouse PCSK9. Serum levels of PCSK9 were measured using the Human 
PCSK9 Quantikine ELISA Kit or Mouse PCSK9 Quantikine ELISA Kit (R&D Systems, Inc., Minneapolis, MN, 
USA), according to the manufacturer’s instructions. Human serum was diluted 1:20 and murine serum 1:200.
Quantification of HDL and LDL/VLDL cholesterol. The HDL and LDL/VLDL cholesterol levels of 
serum were measured using an HDL and LDL/VLDL Quantification Colorimetic/Fluorometic Kit (BioVision 
Incorporated, Milpitas, USA), according to the manufacturer’s instructions. After precipitation, 10 µL of the 
HDL and 20 µL of the LDL/VLDL suspension were used for photometric quantification.
Quantification of oxLDL cholesterol. The oxLDL cholesterol levels of serum were determined by a 
commercial Mouse oxLDL ELISA Kit (Cloud-Clone Corp., Houston, USA), according to the manufacturer’s 
instructions. Samples were diluted 1:100.
Lcat activity assay. The Lcat activity in serum was determined by using a commercial LCAT assay kit 
(Sigma-Aldrich, Taufkirchen, Germany; supplied by Roar Biomedical, Inc., New York, NY) according to the 
manufacturer’s protocol. An amount of 2 µL of undiluted serum were incubated with the intact substrate for 6 h 
at 37 °C.
RNA extraction from tissue, cDNA synthesis and Quantitative Real-Time PCR. Total RNAs 
were extracted from 100 mg liver using QIAzol reagent (Qiagen, Hilden, Germany), followed by a purification 
using RNeasy Mini protocol (Qiagen, Hilden, Germany). Total RNA was treated with DNase I (Macherey-Nagel 
GmbH & Co. KG, Bottrop, Germany) on mini-columns to eliminate genomic DNA. The RNA quantification 
was assessed by using the NanoDrop 2000 spectrophotometer (Thermo Fisher, Schwerte, Germany) and RNA 
quality was determined using the Agilent RNA 6000 Nano Kit (Agilent Technologies, Ratingen, Germany), 
according to the manufacturer’s instructions. First-strand cDNA was synthesized from 1 µg of total RNA for 
each reaction using the SuperScript II Reverse Transcriptase Kit (Thermo Fisher, Schwerte, Germany), accord-
ing to the manufacturer’s instructions. The cDNA was diluted 1:5 or 1:10 with water, depending on the target 
gene, and stored at − 20 °C prior to quantitative real-time PCR (qRT-PCR). The qRT-PCR was performed on a 
LightCycler480 (Roche, Mannheim, Germany) using Lightcycler480 MasterCycler SYBR Green (Roche, Man-
nheim, Germany) to assess the mRNA expression levels of target and reference genes. All intron-spanning prim-
ers used for qRT-PCR analysis were designed with Clone Manager Suite 7 (Scientific & Educational Software), 
synthesized by Biomers (Ulm, Germany) and are listed in the Supplementary Table 1. The PCR thermal cycling 
conditions contained an initial incubation of 5 min at 95 °C, followed by 45 cycles of 10 s denaturation at 95 °C, 
primer-specific annealing for 15 s at 65 °C or 59 °C, and 20 s elongation and detection of the amplicon at 72 °C. 
Finally, a melting curve analysis of the amplicon was performed. Each cDNA sample was run in technical trip-
licates. Water was used as a negative control for each primer pair. The relative amount of target mRNA in each 
sample was calculated using the ΔΔCt method, as previously  described48. Relative mRNA expression levels were 
corrected by PCR efficiency and the reference genes normalization factor, by normalizing target mRNA Ct val-
ues to those of glyceraldehyde-3-phosphate dehydrogenase (Gapdh), hypoxanthine phosphor-ribosyltransferase 
1 (Hprt) and beta-2 microglobulin (ß2m) (6-month-old mice) or Gapdh, Hprt and eukaryotic translation initia-
tion factor 3 subunit A (Eif3a) (12-month-old mice). A cutoff for no detectable mRNA expression was set to a 
Ct value of  3536.
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Quantification of apos. Murine serum apos A-I, A-II, A-IV, B, C-I and E were quantified via tryptic 
proteotypic peptides applying liquid chromatography coupled to tandem mass spectrometry (LC–MS/MS). 
Method parameters including sample preparation were adapted from a standardized targeted proteomics assay 
for human  apos49.
Quantification of free and esterified sterols. Quantification of free and esterified cholesterol, choles-
terol precursors, such as free lanosterol and free zymosterol/desmosterol/7-dehydrocholesterol (zy/de/7dhc), 
and phytosterols, such as brassicasterol, campesterol, β-sitosterol, and stigmasterol (mg/mL), were determined 
as  published50,51.
Statistical analysis. Data are presented as means with corresponding standard error of the means (SD). 
Graphic data processing and statistical analysis were performed with GraphPad Prism 5 (GraphPad Software, 
Inc., CA, USA), using Student’s t tests for two group comparisons (two-tailed) and the non-parametric Mann–
Whitney U test for data which are not Gaussian distributed. Data were checked for normality using the Shap-
iro–Wilk test. From inhomogeneous variations a correction of the t-value according to Welch was carried out. In 
case of more than two groups the comparisons were analyzed using single factor variance analysis with Bonfer-
roni correction. Statistical significance was accepted at p ≤ 0.05.
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